恺兴生命科技

Kaixing Life Science is a clinical-stage biotechnology company based in Shanghai, China, specializing in the development of innovative cell therapies for cancer treatment. The company focuses on next-generation CAR-T and TCR-T technologies designed to overcome the limitations of current immunotherapies, particularly in solid tumors. Their pipeline includes candidates targeting hematological malignancies and various solid cancers such as pancreatic and ovarian cancer. Kaixing leverages advanced genetic engineering to enhance the persistence and efficacy of engineered T cells within the immunosuppressive tumor microenvironment. By integrating research, development, and clinical translation, the company aims to provide curative solutions for patients with refractory or relapsed cancers.